Chiromics



Chiromics is prospecting new molecular space
through creation of Accessible Complexity: unique and diverse drug-like small molecule collections that are stereochemically complex generated by Chiromics proprietary technology.
 
Development

Chiromics LLC Drig Development: CC318 - pain - preclinical / CC318 opioid withdrawl - preclinical

The United States is currently experiencing an epidemic of opioid-related deaths. The continued dependence on, and over prescription of, opioids for pain mitigation is directly linked to this epidemic. With millions of patient's worldwide using opioids without reasonable alternatives and a projected market over $17 billion by 2021, the development of non-opiate based, non-addictive treatment for pain represents a key societal necessity.

Therefore, a clear market opportunity exists to develop and launch non-addictive drugs for the safe and effective treatment of acute and chronic pain in a manner that doesn't use opiates in its base formula.

Chiromics LLC has discovered first-in-class positive allosteric modulators (PAMs) of the μ-opioid receptor (MOR) that have demonstrated in vivo proof of principle. This novel analgesic mechanism represents a breakthrough in the treatment of pain and has the potential for broad use in a variety of medical indication.

Based on in vitro and in vivo profiles, our assets are differentiated from the currently available therapeutics for the treatment of pain with diminished on-target adverse effects.

For more information as to the potential use in treating opioid addiction or analgesia, please contact us at info@chiromics.com


AboutNewsTechnologyResearchServices
PartnershipsContactCareersSitemap
Website by Princeton Internet Group, Inc. (PING)